About PINTaD
Mission
To provide a forum to evaluate, discuss, and recommend methods and strategies for imaging in clinical trials, for the sake of all stakeholders.
Purpose
To give the various stakeholders in imaging clinical trials a voice with which to influence and advance the field, and to further its acceptance by industry and regulatory bodies.
Who we consider a stakeholder
Our forum is deliberately open: we welcome input from regulatory bodies, professional organizations, cooperative groups, and anyone else with a stake in the outcome.
The majority of our members come from pharmaceutical, biotechnology, and medical device industries; contract research organizations; central imaging laboratories; academics, consultants, clinicians, radiologists, and nuclear medicine physicians.
Our History
PINTaD began in 2002 as the PhRMA biomarker working group. As imaging grew in importance within the biomarker space, the group expanded into the extended PhRMA Imaging Group, bringing in imaging vendors, imaging CROs, the National Institutes, regulatory agencies, professional organizations such as the RSNA, key opinion leaders, and academics.
The impetus was a shared observation: the absence of harmonized, standardized processes was damaging the quality, cost, efficiency, and effectiveness of trials that relied on medical imaging. Imaging professionals inside pharmaceutical companies did not yet have the critical mass to meaningfully influence the field. The answer was to build alliances with larger stakeholders.
In 2013 we renamed as the Pharma Imaging Network for Therapeutics and Diagnostics.
Leadership
Current Co-Chairs
Sarah Sherlock
Co-Chair
Head of Clinical Imaging, AstraZeneca
sarah.sherlock@astrazeneca.com
Guenther Brueggenwerth
Co-Chair
Principal Imaging Clinician, Bayer AG
guenther.brueggenwerth@bayer.com
2020–2022 — Fabien Ricard, MD · then Director, Global Clinical Development, Bayer; and Brenda Kurland, PhD · then Senior Principal Statistician, ERT
2013–2020 — Annette Schmid, PhD, Chair · then Senior Scientific Director, Translational Research and Early Clinical, Takeda; and Susanta Sarkar, PhD, Co-Chair · then President, CadenzaMed LLC and Adjunct Associate Professor, Department of Radiology, University of Pennsylvania
2011–2012 — James Conklin, MD, MS · then Senior VP of Medical & Scientific Affairs, ICON
2007–2011 — David Mozley, MD · then Senior Director, Merck & Co.
2004–2007 — Mostafa Analoui, PhD, MS · then Senior Director, Pfizer
2002–2003 — James McLeod, MD · then VP, Schering-Plough
Former Chairs
Current Steering Committee Members
Greg Goldmacher, Perceptive Imaging
Jayant Narang, Takeda
Colin Miller, The Bracken Group
Ira Smallberg, Radmetrix
Luc Bidaut, Independent Consultant
Gregory Sica, Independent Contractor/Consultant
Julie Blair, Merigold LLC
Our membersPINTaD has grown to more than 500 professionals working across the imaging clinical trial industry: pharmaceutical and biotechnology companies, imaging CROs, cooperative groups, research institutions, key opinion leaders, and members affiliated with regulatory agencies.
